PTC Therapeutics announced the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the treatment of pediatric and adult patients with phenylketonuria, including the full spectrum of ages and disease subtypes. The European marketing authorization application is currently under review and the marketing authorization applications for Japan and Brazil are expected to be submitted later in 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Truist healthcare analyst holds an analyst/industry conference call
- PTC Therapeutics price target raised to $32 from $30 at Morgan Stanley
- Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
- PTC Therapeutics price target raised to $62 from $52 at Cantor Fitzgerald
- PTC Therapeutics Faces EMA Rejection, Seeks Re-examination